The pharmaceutical sector once again perfectly interprets what it means to "You like to ignore me today, and you can't afford to climb my feet tomorrow."
Today is a carnival for pharmaceuticals. CanSino , Zhaoyanxin Pharmaceuticals, Wantai Biological hit the daily limit, Medixi , Kanglong Huacheng, Tiger Pharmaceutical and other also has an increase of above 10cm.
Guozheng Pharmaceutical Bio-Index rose by more than 6 points, which is a very exaggerated increase for any index, and this is the second increase this month that is more than 6 points.
not only today, but has been a "medicine" market since October. In Shenwan's first-level industry, Pharmaceutical and Biological ranks first in the industry sector with an increase of 14.16%.
carnival, there are also concerns. Will this medical counterattack be a flash in the pan or a reversal come?
In fact, since October, favorable policies have been one of the main lines of the rebound in medicine.
First, the central bank's fiscal interest subsidy loan policy was promoted in the field of medical and health, helping hospital medical equipment to renew, and then centralized procurement policies tend to mature and moderate.
For example, the centralized procurement policy for electrophysiology and laparoscopic cutting kiss/stapler issued by the Fujian Provincial Medical Insurance Bureau on October 14. Overall, the decline in enterprises is more moderate than the previous centralized procurement of coronary stents and orthopedics, which is conducive to enterprises designing reasonable price reduction ranges and retaining profit margins. The signal that the policy side of
is becoming more mild, which is equivalent to giving a reassurance to a major uncertainty factor in the market.
From the perspective of performance, the pharmaceutical industry has performed well.
In the first half of this year, in addition to the decline in revenue from other biological products and medical consumables revenues over the same period last year, most sub-sector revenues achieved positive growth. In terms of net profit of
, blood products, medical equipment, in vitro diagnosis, diagnostic services, medical R&D outsourcing, etc. have achieved rapid growth.
Next, you can also pay attention to the next third quarter report.
According to the disclosed performance forecast, pharmaceutical stocks performed well overall. WuXi AppTec expects net profit to be 7.38 billion in the first three quarters, an increase of 107% year-on-year; Wantai Bio's net profit in the third quarter was 1.251 billion in the third quarter, an increase of 168% year-on-year. Not to mention the issue of valuation of
. For the Guozheng Biomedical Index, the current valuation is only 25.53 times, which is the lowest point in the past five years and is in a state of deep undervaluation.
(Data from: Choice, 2018/1/2-2022/10/25)
Under the triple support of policy, performance and valuation, whether it is the recent surge or the future recovery, it seems reasonable.
The pharmaceutical industry has always been regarded as "long slope and thick snow". Whether it is in US stock or A stock , the pharmaceutical industry is the cradle of 10 times bull stocks.
However, in the "long slope and thick snow" industry, not every company can grow up. The answers submitted by different companies are different for the same test paper.
Under the centralized procurement policy, the investment logic of medicine is very similar to that of liquor, and you need to pay attention to leading companies.
Currently, the homogeneity of innovative drugs, especially targeted drugs, is relatively serious. The era of bombshells when innovative drugs are launched, is gradually passing. Only those new technologies, scarce technology platforms, differentiated treatment fields, innovative drug delivery methods, etc. can bring a better competitive landscape to enterprises, and only companies with technology precipitation are expected to stand out. How to find such a company
?
National Certificate Bioinformatics Index has given the answer.
Its component accounts for nearly 40%, and chemical pharmaceuticals account for more than 10%. It also includes some CXO companies, which can reduce the uncertainty existing in investing in bioinnovative drug companies and obtain better returns on returns.
Specifically, the top ten heavyweight stocks include vaccines, CXO, bioinnovative drugs and other leading companies in multiple sub-sectors, with a total weight of more than 65%, with a relatively high concentration, sufficient technology quality, and a relatively high performance elasticity.
This index has only corresponding ETF fund - Tianhong Guozheng Biomedical ETF (on-site code: 159859), which can help us get excellent leading pharmaceutical companies into one click.
However, biomedicine has a relatively large volatility and is more suitable for long-term batch investment. If you want to set up fixed investment with one click, you can also choose the off-market connected fund on third-party platforms such as Alipay or Tiantian Fund (Class A: 011040; Class C: 011041).
However, no matter how high-quality the track is, it is impossible to only rise and not fall. After selecting the "three good students" (good industries, good enterprises, and good prices), you will lessen the current ups and downs and downs, learn to passivate market information, just slowly "snowball" in high-quality companies, and win the rose of time.
was recently invited to participate in the Tianhong Index Chief Experience Officer event. If you have the opportunity, share with you some experiences and experiences of investing in index in . I hope to go further together on the road of fixed investment in in index fund.
